Medical Rationale
Erectile dysfunction is among the most common and severe quality-of-life consequences of prostate cancer treatment, affecting 60–90% of men treated with radical prostatectomy and 25–60% treated with radiation therapy. Radical prostatectomy, even nerve-sparing, damages the cavernous nerves (branches of the pelvic splanchnic nerves) that course along the posterolateral prostate and mediate reflexogenic erection. Radiation therapy causes progressive obliterative endarteritis of the cavernous arteries and radiation fibrosis of the corpus cavernosum and penile neurovascular bundle. Androgen deprivation therapy (ADT) suppresses testosterone to castrate levels, abolishing both libido and erectile function via hypothalamic-pituitary-gonadal axis suppression. ED following prostate cancer treatment is expected, universal, and a medically established direct complication.
Key Studies
Sanda MG et al. (2008) N Engl J Med (prostate cancer treatment outcomes); Resnick MJ et al. (2013) N Engl J Med (RP vs radiation ED long-term); Capogrosso P et al. (2019) Eur Urol (ED after prostate cancer treatment); Kim ED et al. (2001) Urology (nerve-sparing RP and ED).
Filing Tips
Prostate cancer treatment records (operative report for RP, radiation treatment plan/dosimetry records, ADT prescription records) directly establish the treatment nexus. Urology records documenting post-treatment ED evaluation and treatment. 38 CFR 4.115b, DC 7522 (erectile dysfunction, with or without penile deformity) carries a 0 percent evaluation, and its footnote directs a review for entitlement to special monthly compensation under 38 CFR 3.350. 38 CFR 3.350(a) provides that special monthly compensation under 38 U.S.C. 1114(k), known as SMC-K, is payable for anatomical loss or loss of use of one or more creative organs, in addition to the basic rate of compensation otherwise payable on the basis of degree of disability, and 38 CFR 3.350(a)(1) states how loss of a creative organ is shown, so the urology examination findings are what carry it. (captures cfr-4.115b, cfr-3.350) A nexus letter from the treating urologist or oncologist tying the dysfunction to the documented prostate cancer treatment belongs in the file.
